| Methods |
Randomised clinical trial. |
| Participants |
Country: Korea.
Sample size: 74.
Post‐randomisation drop‐out(s): 8 (10.8%).
Revised sample size: 66.
Females: 12 (16.2%).
Mean age: 51 years.
Piggyback: not stated.
Conventional: not stated.
Cadaveric donor: not stated.
Live donor: not stated.
Inclusion criteria:
1. Adult patients undergoing primary orthotopic liver transplantation.
Exclusion criteria:
1. Severe cardiovascular, cerebrovascular, pulmonary, or end‐stage renal diseases.
2. Taking medications likely to alter coagulation within two weeks of the study.
3. Allergic reaction to HES. |
| Interventions |
The patients were randomised to the following groups.
Group 1: intervention (n = 31).
Further details: high molecular weight hydroxy ethyl starch.
Group 2: control (n = 35).
Further details: low molecular weight hydroxy ethyl starch. |
| Outcomes |
The outcomes reported were thromboelastography parameters. None of the outcomes included in this review were reported. |
| Notes |
Attempts were made to contact the author in September 2011.
Reason for post‐randomisation drop‐out(s): sampling error or transfusion with blood products. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Comment: This information was not available. |
| Allocation concealment (selection bias) |
Unclear risk |
Comment: This information was not available. |
| Blinding of participants and personnel (performance bias)
All outcomes |
Unclear risk |
Comment: This information was not available. |
| Blinding of outcome assessment (detection bias)
All outcomes |
Unclear risk |
Comment: This information was not available. |
| Incomplete outcome data (attrition bias)
All outcomes |
High risk |
Comment: There were post‐randomisation drop‐outs. |
| Selective reporting (reporting bias) |
High risk |
Comment: Important outcomes were not reported. |
| Vested interest bias |
Unclear risk |
Comment: This information was not available. |
